Macroaxis: Personalized Investing  
Macroaxis Country Selector USA  Change      Macroaxis User Registration Register    Macroaxis User Login Sign In
   
 US Market Open: Feb 9, 12:30 PM 2012 
  NYSE  8086.69  3.71  Index Moved Up   NASDAQ  2924.24  8.38  Index Moved Up 
 and more..
Search
sponsered by
  
  



Processing
Collecting necessary data for PSDV...
1.23
  
pSivida Quote
Intraday
 
pSivida Intraday Quote
One Month
(0.01)  Macroaxis: -0.81 Down   0.81%  
 1.02 Year To Date 5.23 
 1.16 Trading Day  1.23 
    
Diversification Suggestion
Use pSivida to protect against small markets fluctuations. The stock experiences moderate downward daily trend and can be a good diversifier
1 Month Beta vs NYSE ......... 0.33
As returns on NYSE increase, pSivida returns are expected to increase less then the market. However, during bear market, the loss on holding pSivida will be expected to be smaller as well
pSivida Small Beta
    
PSDV Macroaxis: United States NGMpSivida Quote: Bear
pSivida Corp.
http://www.psivida.com
617-926-5000
Trade pSivida
Run Report
 Run Report 
Correlation
 Correlation 
Drug Delivery  
Market Capitalization 25.6M  
Earnings Per Share -0.394  
Today Lowest 1.16  
Book Value Per Share 1.694  
Dr. Paul  Ashton B.Sc., Ph.D. executive Dr. Paul Ashton B.Sc., Ph.D.
Chief Officer, Pres and Director 
 Leonard S. Ross  executive  Leonard S. Ross
Principal Financial Officer, Princi 
 Lori H. Freedman Esq., B.A., J.D. executive  Lori H. Freedman Esq., B.A., J.D.
VP of Corp. Affairs, Gen. Counsel a 
 Marty  Nazzaro  executive  Marty Nazzaro
VP of Operations 
 Brian  Leedman B.Econ., M.B.A. executive  Brian Leedman B.Econ., M.B.A.
VP of Investor Relations 

pSivida fundamentals

    
Open1.21P/B Ratio0.73
Volume13868SectorHealthcare
Last Close1.24FoundedYes
Short Ratio0.90Last Traded2/9/2012
Year High5.23Percent ChangePrice Moved Down 0.81%
Year Low1.02Absolute Change0.01 Price Moved Down
EPS-0.394Index MembershipNot Applicable
Employees26Day High1.23
Day Low1.16Target Price3.00
Current EPS-0.394This Year EPS-0.66
Next Year EPS-0.61Current PENot Applicable
    

pSivida Performance    Embed Financials for pSivida Corp.

    
    
 Embed Financials for pSivida Corp.

pSivida Profile

    
pSivida Corp., together with its subsidiaries, develops drug delivery products for treatment of back-of-the-eye diseases that are administered by implantation, injection, or insertion.
 Macroaxis: United States IXIC   0.29 % Macroaxis: 0.29 Moved Up  
 
 Macroaxis: United States GSPC   0.09 % Macroaxis: 0.09 Moved Up  
 
 Macroaxis: United States NYA   0.05 % Macroaxis: 0.05 Moved Up  
 
 Macroaxis: thisRed PSDV   0.81 % Macroaxis: 0.81 Moved Down  
 
 Live Sentiment  
 Bulls CRU 
 TORONTO Macroaxis: Canada 
 Bought over 400 shares of
 36 minutes ago
for 4.64 
 Bulls DGS 
 TORONTO Macroaxis: Canada 
 Bought over 200 shares of
 36 minutes ago
for 8.58 
 Bulls RIM 
 TORONTO Macroaxis: Canada 
 Bought over 100 shares of
 36 minutes ago
for 16.4 
 Bulls IMN 
 TORONTO Macroaxis: Canada 
 Bought over 20 shares of
 36 minutes ago
for 68.84 
 Bulls SLF 
 TORONTO Macroaxis: Canada 
 Bought over 90 shares of
 36 minutes ago
for 21.17 
    

pSivida 30-Days Moving Rating

    

Macroaxis Total Score 

    
1
Current 30 Days Moving Rating
    
    

Estimated Market Risk

 2.35
  actual daily
 
 60 %
of total potential
 
Market Risk score

Expected Return

 0.06
  actual daily
 
 4 %
of total potential
 
Expected Return score

Risk-Adjusted Return

 0.02
  actual daily
 
 1 %
of total potential
 
Risk-Adjusted Return score
Based on monthly moving average   [ change ] 
Increase Risk-Adjusted return of PSDV by adding it to a well-diversified portfolio
    

 pSivida Last Intraday

    
 
(0.01)Macroaxis: -0.01 Up0.81%
 
1.24,1.24,1.23,1.23,1.23,1.16,1.23
 
1.241.23
    

Latest headlines for pSivida


Alimera, pSivida fall further after FDA rejection

MSN Money - Nov 14, 2011 NEW YORK (AP) - Shares of Alimera Sciences Inc. and pSivida Corp. continued to slide Monday as Wall Street assessed the prospects for their retinal disease treatment Iluvien. THE SPARK: The stocks ... Biotech Wipeout: Alimera, pSivida and Now Emisphere Technologies and Cadence Pharmaceuticals ALIM, PSDV, EMIS, CADX - SmallCap Network Alimera, pSivida shares take a beating on FDA's Iluvien rejection - FierceBiotech The Australian - Australian Life Scientist - Seeking Alpha

Australia up 1.1 pct on Italy progress; pSivida slides

Yahoo!Xtra New Zealand News - Nov 14, 2011 Nov 14 (Reuters) - Australian shares gained 1.1 percent on Monday, led by banks and industrial stocks on relief that Italy has moved swiftly to appoint a new prime minister, aiming to end a crisis ...

pSivida: New 52-Week Low Set Today (PSDV)

Shares of pSivida (NASDAQ:PSDV) traded today at $3.45, breaking its 52-week low. Approximately 1.1 million shares have changed hands today, as compared to an average 30-day volume of 90,000 shares ...

pSivida: New 52-Week Low Set Today (PSDV)

Shares of pSivida (NASDAQ:PSDV) traded today at $3.45, breaking its 52-week low. Approximately 1.1 million shares have changed hands today, as compared to an average 30-day volume of 90,000 shares ...

Alimera, Psivida Shares Drop After U.S. FDA Rejects Eye Drug for Diabetes

Bloomberg - Nov 10, 2011 By Molly Peterson - Fri Nov 11 21:33:52 GMT 2011 Alimera Sciences Inc. (ALIM) plunged 73 percent and Psivida Corp. (PSDV) fell the most in almost seven years after US regulators rejected the ... Alimera plunges as FDA asks for new Iluvien trials - BusinessWeek pSivida Corp. to Hold Monday November 14 Conference Call to Discuss Complete Response Letter for ILUVIEN(R) for DME and pSivida's Product Pipeline - MarketWatch TheStreet.com - Business Wire - StreetInsider.com